-
Patients who receive extended anticoagulation are protected from recurrent VTE while receiving long-term therapy. The clinical benefit is maintained after anticoagulation is discontinued, but the magnitude of the benefit is less pronounced.
-
Following a priority review, the FDA has approved deferasirox, the first oral iron chelator for the treatment of chronic iron overload due to transfusions. It will be marketed by Novartis Pharmaceuticals as Exjade®.
-
-
The ECG in the Figure was obtained from a 77-year-old. woman with a history of "heart problems." What can (and can not) be said about this tracing?
-
Patients in an internal medicine outpatient clinic overwhelmingly preferred both male and female doctors in professional attire with a white coat, and were more willing to share their personal history with them.
-
The majority of chronic stable coronary artery disease patients given 75 mg of EC aspirin daily have adequate inhibition of COX, but younger, heavier, and post MI patients may not.
-
Should Beta-Blockers Remain First Choice in the Treatment of Primary Hypertension?; Obstructive Sleep Apnea as a Risk Factor for Stroke and Death; Cholinesterase Inhibitors for Alzheimers Disease
-
-
Beta-Blockers Therapy for the Treatment of Hypertension; Treatments for Acute Migraine; Statin Therapy for ACS Patients; The Correct Dosing for Onychomycosis; FDA Actions
-
Imiquimod is safe and effective in the treatment of actinic keratoses.
